The health condition/problem studied in this trial is **Helicobacter pylori infection**, which is associated with gastrointestinal disorders such as gastritis, peptic ulcers, and an increased risk of gastric cancer and MALT lymphoma.
Conditions
Interventions
The interventions in the study were two treatment regimens for the eradication of *Helicobacter pylori*:
1. **Concomitant Therapy**: A 10-day regimen consisting of esomeprazole 40 mg twice daily, amo
Sponsors
Holy Spirit University of Kaslik (USEK), School of Medicine and Medical Sciences.
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: The inclusion criteria for the study were: 1. **Positive Helicobacter pylori infection** confirmed through histological findings. 2. **No prior eradication therapy** for *Helicobacter pylori*. 3. **Written informed consent** provided by all participants. These criteria ensured that the study focused on patients with active *H. pylori* infections who had not undergone previous treatment.
Exclusion criteria
Exclusion criteria: The exclusion criteria for the study were as follows: 1. **Recent exposure to antibiotics**. 2. **History of allergy or intolerance** to any of the components in the treatment regimens. 3. **Presence of gastric cancer** confirmed by histological findings. 4. **Patients who had undergone prior eradication therapy** for *Helicobacter pylori*. These criteria ensured the exclusion of patients who might have confounding factors affecting treatment outcomes or safety.
Countries
Lebanon
Contacts
Public ContactJad Chidiac
USEK
Outcome results
None listed